Shyam Kotadia

Shyam Kotadia, on behalf of Rogin, asked for more color on AUCATZYL's Q3 2025 revenue dynamics, specifically if the flat quarter-on-quarter performance was expected given the CMS coding impact, and how to think about Q4 sales and the 2026 trajectory.

Answer

Dr. Christian Itin, CEO of Autolus Therapeutics, confirmed that a relatively flat Q3 trajectory was expected due to the lag in patient enrollment and manufacturing caused by the CMS event in late Q2 and early Q3. He noted that the second half of Q3 ran at the expected clip but declined to give Q4 guidance due to the unknown impact of year-end seasonality (Thanksgiving, ASH, holidays) on the first year of launch. He did not provide specific 2026 trajectory guidance.

Shyam Kotadia asked about the revenue dynamics for AUCATZYL for the remainder of 2025, specifically inquiring if the flat Q3 revenue was expected given the CMS impact, and how to project Q4 sales and the trajectory for 2026.

Answer

CEO Dr. Christian Itin stated that a relatively flat Q3 trajectory was expected due to the CMS event's lag impact, which was fully reversed in the second half of the quarter. He declined to give Q4 guidance due to holiday seasonality and ASH, noting it's too early in the launch to handicap these factors.